Eagle Pharmaceuticals’ Ryanodex (dantrolene sodium) Receives the US FDA’s ODD for the Treatment of Organophosphate Exposure

Shots:

• The US FDA has granted ODD to Eagle’s Ryanodex (dantrolene sodium) as it has the potential to treat brain damage secondary to nerve agent exposure and can protect military personnel and civilians in nerve agent attacks
• The ODD is granted to novel drugs and biologics which are intended for the safe and effective treatment, diagnosis or prevention of rare diseases affecting people less than 200,000 in the US
• If approved, Ryanodex will be the first therapy to treat brain damage secondary to nerve agent exposure

Click here ­to­ read full press release/ article | Ref: Eagle | Image: LinkedIn